Cabaletta Bio, Inc.

CABA ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Balance Sheet
Annual Quarterly

Balance Sheet

Line Item Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024
Assets
Cash & Equivalents $225.1M $116.6M $83.0M $60.2M $145.6M $131.8M $164.0M $170.6M
Accounts Receivable — — — — — — — —
Inventory — — — — — — — —
Total Current Assets $231.0M $122.3M $138.9M $164.6M $198.4M $134.6M $166.7M $185.5M
Property, Plant & Equipment $1.5M $1.6M $1.9M $2.1M $2.4M $2.6M $2.7M $2.8M
Goodwill — — — — — — — —
Intangible Assets (Excl. Goodwill) — — — — — — — —
Total Assets $256.7M $148.1M $165.1M $189.8M $224.5M $165.1M $185.0M $204.4M
Liabilities
Accounts Payable $5.8M $6.4M $6.6M $8.3M $7.2M $6.5M $4.9M $2.2M
Total Current Liabilities $39.9M $41.5M $50.2M $45.7M $41.5M $34.0M $27.1M $22.9M
Long-Term Debt — — — — — — — —
Total Liabilities $46.1M $44.8M $53.0M $50.3M $46.0M $43.6M $32.7M $30.2M
Stockholders' Equity
Retained Earnings $-611.5M $-560.5M $-517.0M $-475.0M $-430.2M $-385.0M $-349.1M $-316.5M
Total Stockholders' Equity $210.6M $103.3M $112.1M $139.5M $178.5M $121.6M $152.3M $174.2M
← Newer Page 1 of 4 Older →